bafetinib

A Bcr-Abl/Lyn dual tyrosine kinase inhibitor, which may suppress the growth of CLL cells by inhibition of Lyn kinase. Imatinib-resistant CLL cells are associated with an overexpression of Lyn kinase, a factor in the proliferation and survival of B-CLL cells. It has no effect on c-Src kinase activity, and may be less toxic than other broad Src family kinase inhibitors. Bafetinib has shown therapeutic potential in phase-II trials in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia.

References in periodicals archive ?

They show that giving the leukemia drugs nilotinib or bafetinib to fly larvae with the equivalent of Fragile X prevented the wild overgrowth of neuron endings associated with the disorder.

Cancer Drugs for Treating Brain Disorders?

The Company completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib.

CytRx to Present at the Cowen & Company 33rd Annual Health Care Conference

That includes two trials for bafetinib, a possible treatment for people with certain advanced forms of leukemia.

Biotechnology company CytRx Corp (Los Angeles CA) said its loss narrowed in 2009 as revenue increased and research and development costs fell

Full browser ?

CITE

Site: Follow: Share:

Open / Close